Targeting sterol alpha‐14 demethylase of Leishmania donovani to fight against leishmaniasis

• Published in: Journal of cellular biochemistry Vol. 122; no. 9; pp. 1037 - 1047
• Main Authors: Tabrez, Shams, Rahman, Fazlur, Ali, Rahat, Akand, Sajjadul Kadir, Alaidarous, Mohammed A., Alshehri, Bader Mohammed, Banawas, Saeed, Dukhyil, Abdul Aziz Bin, Rub, Abdur
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2021
• Subjects: Amastigotes; Annexin V; Apoptosis; avodart; Cell death; FDA; FDA approval; inhibitors; Leishmania; Leishmania donovani; Leishmaniasis; molecular‐docking; Parasites; Parasitic diseases; Promastigotes; Protozoa; Reactive oxygen species; sterol alpha‐14 demethylase; Sterols; Tropical diseases; Vector-borne diseases; inhibitors; sterol alpha-14 demethylase; FDA; avodart; Leishmania; molecular-docking
• ISSN: 0730-2312; 1097-4644
• DOI: 10.1002/jcb.29922

Leishmaniasis is a neglected tropical disease caused by the protozoan parasite Leishmania. It is endemic in more than 89 different countries worldwide. Sterol alpha‐14 demethylase (LdSDM), a sterol biosynthetic pathway enzyme in Leishmania donovani, plays an essential role in parasite survival and proliferation. Here, we used a drug repurposing approach to virtually screen the library of the Food and Drug Administration (FDA)‐approved drugs against LdSDM to identify the potential lead‐drug against leishmaniasis. Zafirlukast and avodart showed the best binding with LdSDM. Zafirlukast was tested for in vitro antileishmanial assay, but no significant effect on L. donovani promastigotes was observed even at higher concentrations. On the other hand, avodart profoundly inhibited parasite growth at relatively lower concentrations. Further, avodart showed a significant decrease in the number of intra‐macrophagic amastigotes. Avodart‐induced reactive oxygen species (ROS) in the parasites in a dose‐dependent manner. ROS induced by avodart led to the induction of apoptosis‐like cell death in the parasites as observed through annexin V/PI staining. Here, for the first time, we reported the antileishmanial activity and its possible mechanism of action of FDA‐approved drug, avodart, establishing a nice example of the drug‐repurposing approach. Our study suggested the possible use of avodart as an effective antileishmanial agent after further detailed validations. Virtual screening of FDA‐approved drug library resulted in the identification of avodart as a potential antileishmanial lead molecule.